Literature DB >> 12902462

Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion.

Andrew L Mellor1, Babak Baban, Phillip Chandler, Brendan Marshall, Kanchan Jhaver, Anna Hansen, Pandelakis A Koni, Makio Iwashima, David H Munn.   

Abstract

In mice, immunoregulatory APCs express the dendritic cell (DC) marker CD11c, and one or more distinctive markers (CD8alpha, B220, DX5). In this study, we show that expression of the tryptophan-degrading enzyme indoleamine 2,3 dioxygenase (IDO) is selectively induced in specific splenic DC subsets when mice were exposed to the synthetic immunomodulatory reagent CTLA4-Ig. CTLA4-Ig did not induce IDO expression in macrophages or lymphoid cells. Induction of IDO completely blocked clonal expansion of T cells from TCR transgenic mice following adoptive transfer, whereas CTLA4-Ig treatment did not block T cell clonal expansion in IDO-deficient recipients. Thus, IDO expression is an inducible feature of specific subsets of DCs, and provides a potential mechanistic explanation for their T cell regulatory properties.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902462     DOI: 10.4049/jimmunol.171.4.1652

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  149 in total

1.  Expression of Stat3 and indoleamine 2, 3-dioxygenase in cornea keratocytes as factor of ocular immune privilege.

Authors:  Jae Wook Yang; Dong Sik Ham; Hyun Woong Kim; Sul Gee Lee; Sae Kwang Park; Su Kil Seo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-10       Impact factor: 3.117

Review 2.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

Review 3.  Identification and characterization of CD8+ suppressor T cells.

Authors:  James C Zimring; Judith A Kapp
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

4.  Human endometrial-derived mesenchymal stem cells suppress inflammation in the central nervous system of EAE mice.

Authors:  J P S Peron; T Jazedje; W N Brandão; P M Perin; M Maluf; L P Evangelista; S Halpern; M G Nisenbaum; C E Czeresnia; M Zatz; N O S Câmara; L V Rizzo
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

5.  Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion.

Authors:  Alexander J Muller; James B DuHadaway; Mee Young Chang; Arivudinambi Ramalingam; Erika Sutanto-Ward; Janette Boulden; Alejandro P Soler; Laura Mandik-Nayak; Susan K Gilmour; George C Prendergast
Journal:  Cancer Immunol Immunother       Date:  2010-07-17       Impact factor: 6.968

6.  Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

Authors:  Madhav D Sharma; Babak Baban; Phillip Chandler; De-Yan Hou; Nagendra Singh; Hideo Yagita; Miyuki Azuma; Bruce R Blazar; Andrew L Mellor; David H Munn
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment.

Authors:  Rong Fu; Yi-Wei Zhang; Hong-Mei Li; Wen-Cong Lv; Li Zhao; Qing-Long Guo; Tao Lu; Stephen J Weiss; Zhi-Yu Li; Zhao-Qiu Wu
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

8.  Phenotypic characterization of regulatory T cells in the human decidua.

Authors:  J Heikkinen; M Möttönen; A Alanen; O Lassila
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

Review 9.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

Review 10.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.